Truth matters. Community matters. Your support makes both possible. LAist is one of the few places where news remains independent and free from political and corporate influence. Stand up for truth and for LAist. Make your year-end tax-deductible gift now.
Cedars-Sinai Sees Early Promise In COVID-19 Treatment Study
A vial of the drug Remdesivir presented this week at a news conference in Germany announcing the start of a trial there. (Ulrich Perrey / AFP via Getty Images)
A small trial of an experimental antiviral drug that could treat COVID-19 patients has shown encouraging results, Cedars-Sinai Hospital officials said today.
Cedars-Sinai is among dozens of sites around the world participating in a clinical trial of the drug Remdesivir. A study about what's happened so far was published Friday in the New England Journal of Medicine.
Cedars-Sinai's director of epidemiology says definitive conclusions cannot be drawn, but results from this group of patients are hopeful.
Keep in mind the sample size is very small. There was also no control group receiving a placebo, a common practice in clinical trials.
According to the study, 61 patients received at least one dose of the drug but only 53 were able to be analyzed. Of those, 22 were in the U.S.
The study found 18 days after the initial dose:
- 36 patients (68%) improved, including 17 of the 30 patients who were receiving mechanical ventilation who were extubated.
- 25 patients (47%) were discharged
- 7 patients (13%) died
Of the sickest patients, those receiving "invasive ventilation" the mortality rate was 18% (6 of 34). There was also one death of a patient not receiving invasive ventilation. The study's authors also reported side effects ranging from a rash and diarrhea to acute kidney injury.
Sponsored message
Our news is free on LAist. To make sure you get our coverage: Sign up for our daily coronavirus newsletter. To support our non-profit public service journalism: Donate Now.
MORE ON CORONAVIRUS:
You come to LAist because you want independent reporting and trustworthy local information. Our newsroom doesn’t answer to shareholders looking to turn a profit. Instead, we answer to you and our connected community. We are free to tell the full truth, to hold power to account without fear or favor, and to follow facts wherever they lead. Our only loyalty is to our audiences and our mission: to inform, engage, and strengthen our community.
Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive before year-end will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.
If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Your tax-deductible donation keeps LAist independent and accessible to everyone.
Right now, LAist has lost $1.7M in annual funding due to Congress clawing back money already approved. The support we receive before year-end will determine how fully our newsroom can continue informing, serving, and strengthening Southern California.
If this story helped you today, please become a monthly member today to help sustain this mission. It just takes 1 minute to donate below.
Your tax-deductible donation keeps LAist independent and accessible to everyone.
Senior Vice President News, Editor in Chief
